

RECEIVED
CENTRAL FAX CENTER
SEP 16 2009

Serial No. 10/694,874
Response filed Sept. 16, 2009

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in this application.

Claims 1-16. (Canceled)

17. (Previously Presented) An isolated Insulin Receptor Substrate-1/2 phospho-specific antibody that binds to human Insulin Receptor Substrate-1 (IRS-1) when phosphorylated at serine 1101 (SEQ ID NO: 1), but does not bind human IRS-1 when not phosphorylated at serine 1101.
18. (Previously Presented) The antibody of claim 17, wherein said antibody further binds to human Insulin Receptor Substrate-2 (IRS-2) when phosphorylated at serine 1149 (SEQ ID NO: 2), but does not bind human IRS-2 when not phosphorylated at serine 1149.
19. (Previously Presented) The antibody of claim 17, wherein said antibody further binds to murine IRS-1 when phosphorylated at serine 1095 (SEQ ID NO: 3), but does not bind murine IRS-1 when not phosphorylated at serine 1095.
20. (Previously Presented) The antibody of claim 17, wherein said antibody further binds to murine IRS-2 when phosphorylated at serine 1138 (SEQ ID NO: 4), but does not bind murine IRS-2 when not phosphorylated at serine 1138.
21. (Previously Presented) An isolated Insulin Receptor Substrate-1/2 phospho-specific antibody that binds to human IRS-2 when phosphorylated at serine 1149 (SEQ ID NO: 2), but does not bind human IRS-2 when not phosphorylated at serine 1149.
22. (Previously Presented) The antibody of claim 21, wherein said antibody further binds to human IRS-1 when phosphorylated at serine 1101 (SEQ ID NO: 1), but does not bind human IRS-1 when not phosphorylated at serine 1101.
23. (Previously Presented) The antibody of claim 21, wherein said antibody further binds to murine IRS-1 when phosphorylated at serine 1095 (SEQ ID NO: 3), but does not bind murine IRS-1 when not phosphorylated at serine 1095.

Serial No. 10/694,874
Response filed Sept. 16, 2009

24. (Currently Amended) The antibody of claim 21 wherein, said antibody further binds to murine IRS-2 when phosphorylated at serine 1138 (SEQ ID NO: 4), but does not bind murine IRS-2 when not phosphorylated at serine ~~1138-25~~ 1138.
25. (Previously Presented) An isolated Insulin Receptor Substrate-1/2 phospho-specific antibody that binds to murine IRS-1 when phosphorylated at serine 1095 (SEQ ID NO: 3), but does not bind murine IRS-1 when not phosphorylated at serine 1095.
26. (Previously Presented) The antibody of claim 25, wherein said antibody further binds to human IRS-1 when phosphorylated at serine 1101 (SEQ ID NO: 1), but does not bind human IRS-1 when not phosphorylated at serine 1101.
27. (Previously Presented) The antibody of claim 25, wherein said antibody further binds to human IRS-2 when phosphorylated at serine 1149 (SEQ ID NO: 2), but does not bind human IRS-2 when not phosphorylated at serine 1149.
28. (Previously Presented) The antibody of claim 25, wherein said antibody further binds to murine IRS-2 when phosphorylated at serine 1138 (SEQ ID NO: 4), but does not bind murine IRS-2 when not phosphorylated at serine 1138.
29. (Previously Presented) An isolated Insulin Receptor Substrate-1/2 specific antibody that binds to murine IRS-2 when phosphorylated at serine 1138 (SEQ ID NO: 4), but does not bind murine IRS-2 when not phosphorylated at serine 1138.
30. (Previously Presented) The antibody of claim 29, wherein said antibody further binds to human IRS-1 when phosphorylated at serine 1101 (SEQ ID NO: 1), but does not bind human IRS-1 when not phosphorylated at serine 1101.
31. (Previously Presented) The antibody of claim 29, wherein said antibody further binds to human IRS-2 when phosphorylated at serine 1149 (SEQ ID NO: 2), but does not bind human IRS-2 when not phosphorylated at serine 1149.
32. (Previously Presented) The antibody of claim 29, wherein said antibody further binds to murine IRS-1 when phosphorylated at serine 1095 (SEQ ID NO: 3), but does not bind murine IRS-1 when not phosphorylated at serine 1095.
33. (Previously Presented) The antibody as in one of claims 17, 21, 25 or 29, wherein said antibody is polyclonal.

Serial No. 10/694,874
Response filed Sept. 16, 2009

34. (Previously Presented) The antibody as in one of claims 17, 21, 25 or 29, wherein said antibody is monoclonal.
35. (Previously Presented) A hybridoma cell line producing any one of the antibodies of claim 34.
36. (Previously Presented) A kit for the detection of phosphorylated human IRS-1 (Ser1101) (SEQ ID NO: 1) in a biological sample, said kit comprising (a) the antibody of claim 17 and (b) at least one secondary antibody conjugated to a detectable group.
37. (Previously Presented) A kit for the detection of phosphorylated human IRS-2 (Ser1149) (SEQ ID NO: 2) in a biological sample, said kit comprising (a) the antibody of claim 21 and (b) at least one secondary antibody conjugated to a detectable group.
38. (Currently Amended) A kit for the detection of PKC theta activity in a biological sample, said kit comprising (a) at least one antibody of claims 17, ~~21, 25~~, or ~~29~~ 21 and (b) at least one secondary antibody conjugated to a detectable group.